CA-NEXON-AMERICA
7.6.2022 15:03:34 CEST | Business Wire | Press release
MapleStory , Nexon ’s original free-to-play, side scrolling 2D MMORPG with an aggressively cute game style, announces the first of its two-part summer update, “Destiny: Remastered,” lands in-game on June 15, filled to the brim with special events, a revamp of all of Explorer jobs, plus a gift package for pre-registering before June 13!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005606/en/
SPECIAL EVENTS
Summer just wouldn’t be summer in MapleStory
without some special, in-game events! It’s time for the season of music and majesty, as new friend Stella comes to experience Maple World first hand. There are a wealth of rewards to collect during the musical summer nights of Starlight Symphony
, plus the return of Tera Burning Plus
and Burning World
. On top of all that, pre-register a character (must be level 61 or above) before 11am PDT on June 13 to get a special Destiny gift package featuring Lil Symphony pets, Angelic Alphabet Damage Skin, a heap of Melody Coins to get a head start in Starlight Symphony, and a Magician of the Sacred Forest outfit!
EXPLORER REVAMP
The Explorer class of characters in MapleStory
has been the backbone of the game for the last seventeen years. These 14 unique Explorer jobs are receiving a complete overhaul of animations, improved skills, new story segments, and more.
The Explorer revamp benefits the following characters:
- Warrior : Hero, Paladin, Dark Knight
- Magician : Arch Mage (Fire/Poison), Arch Mage (Ice/Lightning), Bishop
- Bowman : Bowmaster, Marksman
- Thief : Night Lord, Shadower, Dual Blade
- Pirate : Corsair, Buccaneer, Cannoneer
IMPROVEMENTS GALORE
Incorporated into the “Destiny: Remastered” update are additional improvements, new boss accessories, and boss difficulties so everyone can enjoy a better Maple experience:
- No more Mastery Books ! - Mastery Books are no longer needed to upgrade 4th Job skills.
- Dawn Boss Accessories set - Claim a new set of accessories from bosses to forge a powerful new set.
- New Boss Difficulties - Take on Chosen Seren and Verus Hilla on normal mode and overcome Will on easy difficulty.
BEAN BRIGADE “DESTINY: REMASTERED” SNEAK PEEK
Members of MapleStory
’s content creator program, Bean Brigade
, will be jumping into the test servers early beginning today to give Maplers a sneak peek of all the exciting changes and updates coming to “Destiny: Remastered.” Follow along on Bean Brigade’s dedicated Twitch page
from June 7 through 10.
SUMMER UPDATE PART TWO
Last but not least, Summer Update Part Two, “Destiny: Homecoming,” arrives on July 20
with an all-new homestead feature allowing Maplers to purchase and decorate their very own home! Show off your exquisite taste and home decorating style, and be the envy of every other homeowner in Maple World. Also in Part Two, the Watcher Kalos awaits on top of Karote, the Unending Tower. Win in the battle against this formidable boss to obtain a new Eternal Equipment Set!
Grab your sunscreen and check out everything there is to do in MapleStory this summer!
Assets: HERE
Social Media: Twitch / Facebook / Twitter / YouTube / Website
About MapleStory
https://maplestory.nexon.net
MapleStory
is one of the largest and most active free-to-play, side-scrolling MMORPGs with over 13 million registered players from its Global services alone out of a total seven MapleStory
services around the world. First released in North America in May 2005, the game continues to grow and evolve alongside its passionate community since launching over 17 years ago. There have been over 274 million characters created to date, which would make MapleStory
’s Maple World the 4th highest populated country in the world.
About Nexon America Inc.
https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory
and Mabinogi
for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005606/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom